BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 31518199)

  • 1. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
    Naqvi S; Clothier J; Wright A; Garriboli M
    J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
    Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X
    Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Marque P; Rischmann P; Gamé X
    World J Urol; 2016 May; 34(5):755-61. PubMed ID: 26282099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
    Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study.
    Koh C; Melling CV; Jennings C; Lewis M; Goyal A
    J Pediatr Urol; 2019 Oct; 15(5):552.e1-552.e8. PubMed ID: 31326328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum injection is useless on fibrotic neuropathic bladders.
    Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
    J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Urodynamic Results of Repeated Intradetrusor Onabotulinum Toxin A Injections in Refractory Neurogenic Detrusor Overactivity: Up to 5 Injections in a Cohort of Children With Myelodysplasia.
    Sekerci CA; Tanidir Y; Garayev A; Akbal C; Tarcan T; Simsek F
    Urology; 2018 Jan; 111():168-175. PubMed ID: 28943369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity.
    Reitz A; Denys P; Fermanian C; Schurch B; Comperat E; Chartier-Kastler E
    Eur Urol; 2007 Dec; 52(6):1729-35. PubMed ID: 17884281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.
    Alloussi SH; Lang Ch; Eichel R; Al-Kaabneh A; Seibold J; Schwentner C; Alloussi S
    World J Urol; 2012 Jun; 30(3):367-73. PubMed ID: 21842216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin injections in the management of non-neurogenic overactive bladders in children.
    Léon P; Jolly C; Binet A; Fiquet C; Vilette C; Lefebvre F; Bouché-Pillon-Persyn MA; Poli-Mérol ML
    J Pediatr Surg; 2014 Sep; 49(9):1424-8. PubMed ID: 25148752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
    Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
    J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
    Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
    J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
    Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
    Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
    Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
    Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
    Álvares RA; Araújo ID; Sanches MD
    BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
    Kim SW; Choi JH; Lee YS; Han SW; Im YJ
    Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
    Chen G; Liao L
    Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.
    Ghalayini IF; Al-Ghazo MA; Elnasser ZA
    Int Urol Nephrol; 2009 Dec; 41(4):805-13. PubMed ID: 19184509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.